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Abstract
Background: Vitamin D is an important determinant of bone health and also plays a major role in the regulation
of the immune system. Interestingly, vitamin D status before the start of highly active antiretroviral therapy
(HAART) has been recently associated with HIV disease progression and overall mortality in HIV-positive pregnant
women. We prospectively studied vitamin D status in HIV individuals on HAART in Belgium.
We selected samples from HIV-positive adults starting HAART with a pre-HAART CD4 T-cell count >100 cells/mm
3
followed up for at least 12 months without a treatment change. We compared 25-hydroxyvitamin D plasma
[25-(OH)D] concentration in paired samples before and after 12 months of HAART. 25-(OH)D levels are presented
using two different cut-offs: <20 ng/ml and <30 ng/ml.
Results: Vitamin D deficiency was common before HAART, the frequency of plasma 25-(OH)D concentrations
below 20 ng/ml and 30 below ng/ml was 43.7% and 70.1% respectively. After 12 months on HAART, the frequency
increased to 47.1% and 81.6%.
HAART for 12 months was associated with a significant decrease of plasma 25-(OH)D concentration (p = 0.001).
Decreasing plasma 25-(OH)D concentration on HAART was associated in the multivariate model with NNRTI-based
regimen (p = 0.001) and lower body weight (p = 0.008). Plasma 25-(OH)D concentrations decreased significantly in
both nevirapine and efavirenz-containing regimens but not in PI-treated patients.
Conclusions: Vitamin D deficiency is frequent in HIV-positive individuals and NNRTI therapy further decreases
25-(OH)D concentrations. Consequently, vitamin D status need to be checked regularly in all HIV-infected patients
and vitamin D supplementation should be given when needed.
Background
Vitamin D status is an important determinant of bone
health. Vitamin D deficiency increases the risk of osteo-
porosis and fractures and in its most severe form causes
rickets in children and osteomalacia in adults. In addi-
tion, a large number of studies indicate that vitamin D
also plays an important role in insulin secretion, lipid
metabolism, autoimmune disorders, cell proliferation,
and cardiovascular diseases [1-8].
The main determinant of vitamin D status is the intra-
epidermal conversion of pre-vitamin D into vitamin D
by ultra violet radiation. As a consequence, increased
skin pigmentation and low sunlight exposure are risk
factors for vitamin D deficiency [2]. Cholecalciferol is
metabolized into 25-dihydroxyvitamin D [25-(OH)D] in
the liver and into its active form 1,25-dihydroxyvitamin
D [1,25-(OH)2D] in the kidney and peripheral cells such
as activated immune cells [8] by two successive hydro-
xylations by cytochromes P450 [9]. Both 1,25-(OH)2D
and 25-(OH)D are catabolized by the cytochrome
CYP24 [9]. In target cells such as immune cells,
1,25-(OH)2D is converted locally at the site of action
[8]. Due to its longer half-life of 15 days, 25-(OH)D is
considered the best marker of vitamin D status [8].
Although there is no agreement among international
experts on the most appropriate cut-off value for
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below 20 ng/ml are considered as deficient [2]. How-
ever, a value above 30 ng/ml has been suggested to be
associated in the general population with better health
outcomes such as higher bone mineral density, less falls
and fractures as well as protection against cancer [10].
Lower vitamin D level has recently been associated with
increased mortality in the general population [11] as
well as with HIV disease progression and overall mortal-
ity in a cohort of Tanzanian pregnant women with HIV
infection [12].
Paul et al. showed that vitamin D deficiency was more
prevalent among HIV-positive patients treated with
HAART when compared to HAART-naive patients and
negative controls [13], however, Ramayo et al. showed
opposite results [14]. In addition, HAART may impair
vitamin D metabolism [15,16] as shown by some in vitro
studies. Cozzolino et al. [16] demonstrated the inhibition
by protease inhibitors (PIs) of the 25-hydroxylase and the
1a-hydroxylase involved in vitamin D metabolism. Ellfolk
et al. [17] showed the inhibition of the 25-hydroxylase by
efavirenz, a non-nucleoside reverse transcriptase inhibi-
tor (NNRTI).
Vitamin D deficiency and bone disease in HAART
patients [14,18,19] have been associated with NNRTIs
[20-22], as well as tenofovir [23,24], and PIs [19,24-26].
However, there is a lack of longitudinal studies on vita-
min D variation during HAART; therefore we studied
vitamin D status in a longitudinal cohort study of AIDS
patients during the first year of HAART.
Methods
Subjects
Subjects were HIV-positive individuals belonging to the
outpatient cohort of the Institute of Tropical Medicine
(ITM) in Antwerp, Belgium. Antwerp is situated on the
51
st degree of latitude and receives 1000 hours of sun
per year, half the exposure seen at the equator.
Using the ITM cohort electronic database we selected
retrospectively patients fitting the following criteria: (a)
HIV-positive adults starting HAART with CD4 T-cell
counts >100 cells/mm
3; (b) followed up for at least
12 months; (c) without a treatment change in the first
year of HAART. Individuals with a CD4 T-cell count
below 100 cell/mm
3 were excluded as they are often
acutely unwell and may have other factors contributing
to vitamin D deficiency.
Individuals were started either on a PI-based or on an
NNRTI-based regimen. Patients on NNRTI were either
on Nevirapine (= 20) or on Efavirenz (n = 23). Sixty-six
percent (n = 29) of patients on PI were on a boosted regi-
men with Ritonavir. Twenty-seven individuals were tak-
ing Tenofovir; 18 in combination with NNRTIs and 8
with PIs. Patients taking corticosteroids, suffering from
“severe renal disease” or “severe liver disease”,o rw i t ha n
active granulomatous disease such as active tuberculosis,
sarcoidosis and Crohn’s disease were excluded. “Severe
renal disease” was defined as urea and creatinine twofold
above the normal reference values. “Severe liver disease”
was defined as a patient having both elevated alanine
aminotransferase and aspartate aminotransferase 5 times
above the normal reference values.
All subjects had signed an informed consent allowing
additional investigation for research purpose on the
stored plasma samples left over of routine blood testing.
The study was approved by the institutional review
board of the ITM.
Study design
We selected individuals who had stored samples avail-
able at the start of HAART and 12 months later. We
compared paired pre-HAART and post-HAART sam-
ples. The pre-HAART sample was drawn between the
start of HAART and maximum 3 months before it.
The 12 months sample was drawn minimum 3
months before and maximum 3 months after 12
months of HAART.
Clinical data
Clinical data were extracted and analyzed anonymously.
We recorded the following variables: sex, skin color, sea-
son, age, weight, CD4 T-cell nadir and pre-HAART
CD4 T-cell level, viral load, HIV disease stage, HAART
regimen, total cholesterol, HDL-C, and LDL-C. No data
on non prescribed vitamin D supplementation or sun
exposure were routinely collected.
Laboratory analysis
Plasma samples were selected among stored samples
obtained between 1997 and 2009. Plasma had been iso-
lated by centrifugation of blood drawn on ethylenedia-
minetetraacetic acid (EDTA)-containing tubes and
aliquots had been kept in a -80°C freezer.
Total plasma 25-(OH)D was measured by radioimmu-
noassay (DiaSorin). The interassay coefficient of varia-
tion was 9-13%. The quality control was performed by
the vitamin D External Quality Assurance Survey
(DEQAS). All samples were measured in duplicate. CD4
T-cell count was determined by standard flow cytometry
(FACScalibur, Becton Dickinson). Viral load was mea-
sured with the Cobas Amplicor HIV-1 (Roche). Total
cholesterol, HDL-C, and LDL level were determined by
automated standard laboratory techniques.
Vitamin D status
Plasma 25-(OH)D concentrations are presented using
two different cut-offs, <20 ng/ml (50 nmol/l) and
<30 ng/ml (75 nmol/l).
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All statistical analyses were performed with STATA and
R software. Pre-HAART data was summarized using
counts and percentages, means and standard deviations
for normally distributed data, and median (interquartile
range, IQR) for non-normal continuous variables. The
difference between PI and NNRTI groups was assessed
by Fisher’s exact test for percentages, t-test for means
and Mann-Whitney for medians. Normality was assessed
using graphical methods and confirmed by D’agostino
and Pearson omnibus normality test. Within-group or
overall changes in vitamin D levels were assessed using
a paired t-test. Logistic regression or linear regression
methods were used to study the relation between the
predictors and vitamin D. A threshold of p < 0,1 was
used for variable inclusion in the multivariate model,
which was then simplified by backward elimination.
P-values presented in the text refer to the final statistical
model obtained.
Results
Subject characteristics
Among the 194 patients fitting the inclusion criteria,
plasma samples were available at both pre-HAART and
12 months for 89 patients. Two patients were excluded
because of chronic liver disease. None of the patients
had renal insufficiency, a known granulomatous disease
or were treated with corticosteroids during the study
period. A mean ± SD of 381 ± 39 days was observed
between both time points.
The pre-HAART population characteristics are sum-
marized in Table 1. No significant differences at baseline
were observed between patients on PI and NNRTI-
based regimen. The “dark skin” group included 17 indi-
viduals from Central and Southern Africa; the ‘light
skin” group included 68 Caucasians, one Moroccan and
one Ecuadorian.
Risk of vitamin D deficiency in HIV individuals before
HAART
Before HAART, 43.7% and 70.1% of the individuals had
plasma 25-(OH)D concentrations below 20 ng/ml and
30 ng/ml, respectively. In multivariate analysis, dark-
skinned individuals had 8.9 and 11.2 times more risk
than light-skinned individuals to present with plasma
25-(OH)D concentrations below 20 ng/ml and 30 ng/ml
(p = 0,001 and 0,026), respectively. In addition, the pre-
valence of plasma 25-(OH)D concentrations below 30
ng/ml was higher in winter compared to summer (p =
0.001) and fall (p = 0.020). There was no significant
effect of gender, age, weight or HIV disease stage, pre-
HAART CD4 T-cell count or CD4 T-cell nadir, or viral
load on vitamin D levels.
Risk of vitamin D deficiency of HIV individuals
during HAART
After 12 months on HAART, 47.1% and 81.6% of indivi-
duals has plasma 25-(OH)D concentrations below 20
ng/ml and 30 ng/ml respectively. Individuals with a
darker skin color or being treated by a NNRTI-based
regimen presented an increased risk of having plasma
25-(OH)D concentrations lower than 20 ng/ml (respec-
tively 6 and 3 fold; p = 0,006 and p = 0,020). Individuals
with a low body weight were 4.7 times more at a risk of
having plasma 25-(OH)D concentrations below
30 ng/ml (p = 0,026). There was no influence of sex,
sampling season, pre-HAART CD4-T cell count and
CD4 T-cell count nadir, viral load and HIV stage.
When analyzing paired pre-HAART and post-HAART
samples from individuals on HAART for 12 months, we
observed a significant decrease of plasma 25-(OH)D con-
centration in the studied population (Table 2). The
decrease of 25-(OH)D was associated in the multivariate
model to NNRTI-based regimen (p = 0.001) and to a
lower body weight (p = 0.008). Moreover, plasma 25-(OH)
D concentration decreased significantly after 12 months
on NNRTI regimen (both on nevirapine and on efavirenz),
Table 1 Pre-HAART characteristics of the study
population
Variables NNRTI PI p
value
n = 43 N = 44
25-(OH)D (ng/ml) mean ± SD 26.6 ± 13.5 22.6 ± 8.9 0.101
Sex Male n (%) 38 (88.4) 34 (77.3) 0.256
Dark skin color n (%) 7 (16.3) 10 (22.7) 0.590
Pre-HAART
sampling
Winter n (%) 15 (34.9) 17 (38.6) 0.657
Spring n (%) 5 (11.6) 8 (18.2)
Summer n (%) 11 (25.6) 11 (25.0)
Fall n (%) 12 (27.9) 8 (18.2)
Age (years) median
(IQR)
38.6
(30.8;44.8)
37 (31.8;44.6) 0.929
Weight (Kg)
a median
(IQR)
73 (68;85) 70.5 (65.3;83.5) 0.675
CD4 (cells/mm
3)
Nadir median
(IQR)
224
(181;292)
247.5
(182;314.5)
0.61
pre-HAART median
(IQR)
254
(183;338)
299 (241;390.5) 0.052
Viral Load (log10) median
(IQR)
5.24
(4.95;5.53)
5.5 (4.97;5.86) 0.168
HIV stage (CDC)
A n (%) 31 (72.1) 32 (72.7) 0.640
B n (%) 8 (18.6) 6 (13.6)
C n (%) 4 (9.3) 6 (13.6)
PI: Protease inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitors;
SD: Standard deviation; IQR: Interquartile range;
a n=8 5
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association between the use of tenofovir and a decrease in
vitamin D levels (p = 0.665; data not shown).
Changes in cholesterol HDL-C and LDL-C levels on HAART
After one year of HAART, we observed a significant
increase in cholesterol concentration (from 168.5 to
202.5 mg/dl; p < 0.001; data not shown) and HDL-C
levels (from 40.8 and 46.6 mg/dl; p = 0.002; data not
shown). LDL-C level did not increase significantly
(p = 0.168; data not shown). There was no association
between the increase of lipids and the pre-HAART vita-
min D status or with the type of HAART.
Discussion
Our study shows a high prevalence of vitamin D defi-
ciency in HIV-infected individuals as observed by others
[13,27,28]. As reported in the general population [2,29],
vitamin D deficiency during summer and fall was lower
than during winter.
We also showed that a NNRTI-based treatment was
associated with a significant decrease of 25(OH)D
plasma concentration after 12 months on HAART.
Similarly to our findings, Van den Bout-van den Beukel
[21] described a prevalence of vitamin D deficiency of
62% in dark-skinned individuals in a cross-sectional
study of HIV-positive individuals. In their study, patients
on an NNRTI-based therapy had lower vitamin D levels
than those on a PI-based therapy.
Decreased bone mineral density is often described in
cross sectional studies in patients on tenofovir (NRTI)
[23,30] or PIs [19,24-26]. However, we and others found
an association between NNRTI-based regimen and vita-
min D levels [21,22]. The lack of concordant findings on
the effect of HAART on bone mineral density and vita-
min D might result from the direct action of antiretro-
viral drugs on osteoclasts and osteoblasts [26,31,32].
The effect of NRTI drugs on vitamin D metabolism has
never been studied but interactions are unlikely as
NRTIs are not metabolized by cytochromes [33]. In con-
trast, PI and NNRTI drugs have been shown to interfere
with cytochromes involved in the vitamin D metabolism
(e.g. NNRTI induce CYP3A4; PIs inhibit CYP3A4)
[9,16,17,33-35]. The role of each antiretroviral drug par-
ticularly from the NNRTI family on vitamin D metabo-
lism should be evaluated further to better understand
Table 2 Determinants of 25(OH)D (ng/ml) decrease
on HAART
Variable 25(OH)D (CI)
pre-HAART
25(OH)D (CI)
post-HAART
Adj p
Population 24.6 (22.1;27.0) 22.0 (19.8;24.1) 0.001*
Sex 0.668
M 25.6 (22.8;28.4) 22.8 (20.4;25.3)
F 19.6 (14.8;24.4) 17.8 (14.0;21.6)
Skin color 0.195
Light 26.7 (24.0;29.4) 23.6 (21.2;26.0)
Dark 15.8 (11.9;19.7) 15.3 (11.6;19.0)
Pre-HAART sampling 0.127
Winter 21.9 (18.1;25.6) 19.8 (16.2;23.5)
Spring 22.1 (16.5;27.6) 22.4 (19.3;25.5)
Summer 29.8 (24.2;35.4) 22.4 (19.7;29.0)
Fall 24.8 (19.1;30.5) 22.5 (16.8;28.2)
Age 0.644
<35 years 24.9 (21.0;28.7) 22.2 (18.6;25.8)
35-50 years 24.2 (20.2;28.2) 21.2 (17.8;24.5)
>50 years 24.8 (20.0;29.6) 24.2 (19.2;29.2)
Weight (Kg) 0.008
≤70 23.0 (19.4;26.6) 18.5 (16.2;20.9)
>70 25.8 (22.4;29.2) 24.8 (21.4;28.1)
CD4 (CD4/mm
3) nadir 0.160
≤200 25.4 (21.0;29.8) 21.3 (18.2;24.5)
>200 24.1 (21.1;27.1) 22.3 (19.4;25.3)
CD4 (CD4/mm
3) pre-HAART 0.174
≤200 25.9 (20.5;31.4) 21.5 (17.4;25.6)
>200 24.1 (21.3;26.9) 22.1 (19.5;24.8)
Viral Load (log10) 0.666
>5 25.7 (22.9;28.6) 22.9 (20.3;25.6)
≤5 21.7 (16.7;26.6) 19.6 (15.8;23.5)
HIV stage (CDC) 0.760
A 25.4 (22.4;28.4) 22.7 (20.0;25.3)
B 24.3 (18.0;30.5) 21.0 (15.7;26.4)
C 19.8 (13.0;26.5) 18.7 (11.8;25.6)
Therapy 0.001
NNRTI 26.6 (22.5;30.8) 21.6 (17.8;25.5)
PI 22.6 (19.9;25.3) 22.3 (20.1;24.6)
p: p-value for comparison between groups (linear regression); adj p: p-value
from final multivariate model (after backwards elimination); CI: 95%
confidence interval; * non adjusted p value
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Figure 1 plasma 25(OH)D concentration pre-HAART and after
12 months in individuals on NNRTI-based regimen (Nevirapine
and Efavirenz) and PI-based regimen. PI: protease inhibitor.
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metabolism.
Our data show that patients with a body weight ≤
70 kg had a higher risk of plasma 25-(OH)D concentra-
tion below 30 ng/ml after one year on HAART. A simi-
lar association has been reported, in HIV-infected
individuals with BMI and vitamin D status [36]. These
results are different from those of non HIV-infected
patients, where obesity is associated with lower plasma
25-(OH)D concentrations [37] and a slower increase of
vitamin D concentration in response to UVB irradiation.
In non-HIV infected individuals, this has been explained
by an altered release of vitamin D from the skin into
the circulation, and the decreased bioavailability of vita-
min D by deposition in body fat compartment [37].
This study has several limitations. The small sample
size precluded determination of whether the decrease of
plasma 25-(OH)D concentration was associated with the
use of a certain HAART combination. In addition, the
retrospective design and the lack of detailed information
about UV radiation exposure and over the counter mul-
tivitamin supplementation limited our study.
Our results suggest that HIV patients and particularly
those treated with HAART represent a population with
higher risk of vitamin D deficiency. Beyond bone health,
vitamin D deficiency is associated with many chronic
diseases such as cancer, cardiovascular disease, diabetes
and immunological diseases including HIV as well as
chronic pain in HIV-infected individuals [10,11,38-41].
Vitamin D supplementation to maintain an optimal
plasma 25-(OH)D concentration above 30 ng/ml is an
inexpensive and a safe measure as vitamin D toxicity is
only observed at plasma 25-(OH)D concentration higher
than 150 ng/ml [2]. Therefore, clinicians taking care of
HIV patients should be aware of the risk of vitamin D
deficiency associated with HIV and HAART and the
benefits of its supplementation.
Conclusions
In conclusion, our findings suggest that vitamin D defi-
ciency is highly prevalent in HIV individuals and that
NNRTI therapy further decreases 25-(OH)D concentra-
tions. Consequently, vitamin D status need to be
checked regularly in all HIV-infected patients and vita-
min D supplementation should be given when needed.
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